TURN-KEY
DRUG DISCOVERY
Aligning R&D with business and IP
BUILT
BY INNOVATORS
FOR INNOVATORS
Dalriada’s Turn-Key Drug Discovery model is specifically designed to provide ultimate support for semi-virtual lean biotechs developing small molecule therapies.
We uniquely integrate internal R&D, end-to-end program management, business and IP support to unlock the most rapid and agile program execution and ultimately the fastest route to the clinic.
We focus on value building for each client and partner and conduct all programs with an R&D-to-milestone approach. Drawing experience from Pharma, Biotech, VC, and Academia, Dalriada’s team equally understands both the science and business needs, which allows for a seamless collaboration with the biotech client or a fully autonomous project execution.
THREE PILLARS
OF TURN-KEY
MODEL
1
2
3
Through unique integration of R&D, business and IP, we unlock the most agile program execution and rapid advancement of the asset
End-to-End Program Design and Management
-
Expanding and jump-starting product pipelines
-
Program development
-
Data room and due diligence management
-
R&D out-sourcing management
-
Attracting KOLs and consultants
Business and IP Support
-
IP strategy/searches
-
Industry Positioning/Product Roadmap
-
Investment, partnership and licensing consulting
-
Support in company building
Internal Top
Quality R&D
-
Accelerated hit-to-lead and lead optimization through chemistry-biology integration
-
Custom assay development
for even the most innovative projects:
-
MedChem
-
In vitro pharmacology
-
Cell Biology
-
PK / ADME
OUR TRACK RECORD
WHY PARTNER
WITH US
Proprietary cascade
for targeted covalent
inhibitors discovery
and development
Most Rapid and Agile Program Execution
-
Focused teams built for each project within <2 weeks
-
Internal integrated chemistry-biology R&D significantly accelerates the
hit-to-lead and lead optimization cycles
-
Shift the team size and composition any time as the project advances or expands
Accelerated
Value Building
IP-focused Approach
-
Ongoing Pharma, VC, and biotech
insight into each project
-
R&D-to-milestone approach – from program planning to passing due diligence
-
Jump-starting and expanding pipelines
-
Scientific team trained
by top legal firms
-
Experience with conservative and highly aggressive IP strategies
Customized Solution
for Every Project
Innovation-driven
Autonomous
Project Execution
-
Dedicated R&D-business-IP team built for each project
-
Development of custom programs and screening cascades tailored specifically
to the project and business needs
-
Up-to-date with science
-
Custom assay development for most innovative projects
-
Monitoring and adapting to recent industry developments
-
Implementing break-through innovation
-
Projects executed fully
autonomously by Dalriada or in a seamless collaboration with a client
TOP
STANDARDS
OUR EXPERTISE
Small molecule therapeutics
Discovery to
IND-enabling
Kinase
Inhibitors
Proprietary Cascade
for Targeted Covalent Inhibitors
Protein Degraders
Protein-protein Interaction
Inhibitors
GPCRs
